Analyst Price Target is $36.00
▲ +50.75% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Monte Rosa Therapeutics in the last 3 months. The average price target is $36.00, with a high forecast of $40.00 and a low forecast of $30.00. The average price target represents a 50.75% upside from the last price of $23.88.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Monte Rosa Therapeutics.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.